| D007231 |
Infant, Newborn |
An infant during the first 28 days after birth. |
Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants |
|
| D008297 |
Male |
|
Males |
|
| D003561 |
Cytarabine |
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) |
Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C |
|
| D004314 |
Down Syndrome |
A chromosome disorder associated either with an extra CHROMOSOME 21 or an effective TRISOMY for chromosome 21. Clinical manifestations include HYPOTONIA, short stature, BRACHYCEPHALY, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, single transverse palmar crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213) |
Mongolism,Trisomy 21,47,XX,+21,47,XY,+21,Down Syndrome, Partial Trisomy 21,Down's Syndrome,Partial Trisomy 21 Down Syndrome,Trisomy 21, Meiotic Nondisjunction,Trisomy 21, Mitotic Nondisjunction,Trisomy G,Downs Syndrome,Syndrome, Down,Syndrome, Down's |
|
| D005078 |
Exchange Transfusion, Whole Blood |
Repetitive withdrawal of small amounts of blood and replacement with donor blood until a large proportion of the blood volume has been exchanged. Used in treatment of fetal erythroblastosis, hepatic coma, sickle cell anemia, disseminated intravascular coagulation, septicemia, burns, thrombotic thrombopenic purpura, and fulminant malaria. |
|
|
| D005260 |
Female |
|
Females |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D000964 |
Antimetabolites, Antineoplastic |
Antimetabolites that are useful in cancer chemotherapy. |
Antineoplastic Antimetabolites |
|
| D015160 |
Hydrops Fetalis |
Abnormal accumulation of serous fluid in two or more fetal compartments, such as SKIN; PLEURA; PERICARDIUM; PLACENTA; PERITONEUM; AMNIOTIC FLUID. General fetal EDEMA may be of non-immunologic origin, or of immunologic origin as in the case of ERYTHROBLASTOSIS FETALIS. |
Edema, Fetal,Fetal Edema,Fetal Hydrops,Familial Non-Immune Hydrops Fetalis,Hydrops Fetalis Nonimmune,Hydrops Fetalis, Idiopathic,Hydrops Fetalis, Immune,Hydrops Fetalis, Non-Immune,Hydrops Fetalis, Nonimmune,Idiopathic Hydrops Fetalis,Immune Hydrops Fetalis,Non-Immune Hydrops Fetalis,Familial Non Immune Hydrops Fetalis,Fetali, Idiopathic Hydrops,Fetalis Nonimmune, Hydrops,Fetalis Nonimmunes, Hydrops,Fetalis, Idiopathic Hydrops,Hydrops Fetali, Idiopathic,Hydrops Fetali, Nonimmune,Hydrops Fetalis Nonimmunes,Hydrops, Fetal,Idiopathic Hydrops Fetali,Nonimmune Hydrops Fetali,Nonimmune Hydrops Fetalis,Nonimmune, Hydrops Fetalis,Nonimmunes, Hydrops Fetalis |
|
| D038042 |
Myelopoiesis |
Formation of MYELOID CELLS from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW via MYELOID STEM CELLS. Myelopoiesis generally refers to the production of leukocytes in blood, such as MONOCYTES and GRANULOCYTES. This process also produces precursor cells for MACROPHAGE and DENDRITIC CELLS found in the lymphoid tissue. |
|
|